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Abstract
Lippia alba (Mill.) N.E. Brown (Verbenaceae) is widely used in different regions of Central and South America as a tranquilizer. 
The plant’s anxiolytic properties, however, merit investigation. The present study evaluated the effects of repeated daily (14 
days) intraperitoneal (ip) treatment with an essential oil (EO) from a chemotype of L. alba (LA, chemotype II, 12.5 and 25 mg/
kg; N = 6-8) and (R)-(-)-carvone (25 mg/kg; N = 8-12), the main constituent of this chemotype, on male Wistar rats (weighing 
250 g at the beginning of the experiments) submitted to the elevated T-maze (ETM). The ETM allows the measurement of two 
defensive responses: inhibitory avoidance and one-way escape. In terms of psychopathology, these responses have been re-
lated to generalized anxiety and panic disorder, respectively. Treatment with the EO impaired ETM avoidance latencies, without 
altering escape, in a way similar to the reference drug diazepam (P < 0.05) (avoidance 2: control = 84.6 ± 35.2; EO 12.5 mg/kg 
= 11.8 ± 3.8; EO 25 mg/kg = 14.6 ± 2.7; diazepam = 7 ± 2.1). (R)-(-)-carvone also significantly altered this same response (P 
< 0.05; avoidance 1: control = 91.9 ± 31.5; carvone = 11.6 ± 1.8; diazepam = 8.1 ± 3.3). These results were not due to motor 
changes since no significant effects were detected in an open field. These observations suggest that LA exerts anxiolytic-like 
effects on a specific subset of defensive behaviors that have been implicated in generalized anxiety disorder, and suggest that 
carvone is one of the constituents of LA responsible for its action as a tranquilizer. 
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Lippia alba (Mill.) N.E. Brown Verbenaceae (LA) is an 
aromatic shrub, widely used in Central and South America 
for the treatment of different clinical conditions such as 
digestive, respiratory and cardiovascular disorders and as 
an antiseptic, analgesic and tranquilizer (1). 
The results of experimental studies conducted with 
LA are generally consistent with its traditional uses. Thus, 
antibacterial and antifungal activities have been shown for 
different root and leaf extracts (2,3) and antiviral activity was 
observed with an ethanol leaf extract (4). Also anxiolytic 
effects in the elevated plus-maze have been previously 
shown after acute ip administration to mice of essential oils 
(EOs) from two different chemotypes of LA (5) (chemotype 
I, two subtypes, i.e., subtype 1: 55% citral, 10% β-myrcene 
and subtype 2: 64% citral, 12% limonene; chemotype II: 
55% carvone, 23% limonene; doses ranging from 25-200 
mg/kg) (6). 
However, tests with some of the isolated constituents 
(citral, myrcene and limonene, 25-200 mg/kg, ip) of the 
three EOs showed inconsistent results. Although these 
constituents exhibited sedative activity when administered 
acutely to rats (muscle relaxation in the rota-rod, decreases 
in the number of rearings and groomings in the open-field, 
and potentiation of pentobarbital-induced sleeping time), 
they did not exhibit an anxiolytic effect in the elevated 
plus-maze, but rather a slight anxiogenic effect at higher 
doses (7). This inconsistency questions the relevance of 
any conclusion concerning the anxiolytic properties of LA 
(1). Therefore, further investigations on the plant’s use as 
a tranquilizer are still warranted.
In this respect, it should be pointed out that, although 
important as a first step for the evaluation of the anxiolytic 
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properties of LA, the above studies (6,7) were performed 
with a single animal model, the elevated plus-maze. Even 
though the model is widely used, it has failed to detect 
the effect of non-benzodiazepine anxiolytics (8,9). Some 
investigators have suggested that this may occur because 
the elevated plus-maze is a “mixed” animal model, that is, 
one that does not separate different types of fear/anxiety 
(8). According to the DSM-IV-TR classification of psychiatric 
disorders, clinical anxiety is a heterogeneous phenomenon, 
comprising distinctive pathological conditions, such as 
generalized anxiety disorder (GAD), panic and phobias 
- these conditions being unequally affected by pharmaco-
logical therapy. On this basis, there is a growing body of 
evidence suggesting that anxiety, as operationally defined 
in a given animal model, may differ from that generated in 
other models concerning its nature (if innate or learned), 
its response to the effects of drugs and environmental ma-
nipulations, and its underlying neural substrate (10). On the 
basis of this evidence, efforts have been made to validate 
experimental models specifically related to certain kinds of 
anxiety disorders (10). A model that measures behavioral 
responses particularly related to specific subtypes of anxiety 
is the elevated T-maze (ETM) (11-14). 
Although derived from the elevated plus-maze, the 
ETM allows the measurement of two subtypes of anxiety-
related responses in the same rat, i.e., inhibitory avoidance 
and one-way escape. Compounds representative of three 
classes of anxiolytics, namely the agonist of benzodiazepine 
receptors diazepam (DZP), the serotonin (5-HT) 1A agonist 
buspirone, and the nonselective 5-HT2 antagonist ritanserin, 
have been shown to selectively impair inhibitory avoidance 
while leaving one-way escape unchanged (11,12). These 
results are compatible with the view that inhibitory avoidance 
is related to GAD. In contrast, the escape task is insensi-
tive to different classes of anxiolytics and is impaired by 
chronic, but not acute administration of imipramine (13), 
clomipramine and fluoxetine (14), drugs that are used to 
treat panic disorder. As a result, one-way escape in the ETM 
has been used as an animal model of panic. 
The purpose of the present study was to further inves-
tigate the anxiolytic properties of LA by using the ETM, 
a model that allows the measurement of two different 
anxiety-related responses, one associated with GAD and 
the other with panic disorder. Since some pharmacologi-
cal compounds have been shown to ameliorate specific 
subtypes of anxiety disorders (or to alter particular types 
of behavioral responses) only after repeated treatment 
(13-15), this regimen of administration was chosen. In 
the present study, male Wistar rats were treated daily for 
14 days (12.5 and 25 mg/kg, ip) with chemotype II, and 
subsequently tested in the ETM (experiment 1). We also 
determined the effects of repeated treatment with (R)-(-)-
carvone, one of the main constituents of this chemotype, 
on the behavior of animals tested in the ETM (experiment 
2). Among the main constituents of the three EOs previ-
ously investigated (6), carvone was the only one not tested 
for anxiolysis. For both experiments, DZP was used as a 
positive control. In order to avoid confounding results due 
to treatment effects on locomotor activity, animals were 
also tested in an open field. 
Material and Methods
Animals
Male Wistar rats (approximately 250 g) bred in the 
animal house of Universidade de São Paulo, Ribeirão 
Preto Campus (experiment 1), or of Universidade Federal 
de São Paulo, Brazil (experiment 2), were housed 5-6 per 
cage until the ETM experiments. Room temperature was 
controlled (23 ± 1°C) and lights were kept on from 7:00 am 
to 7:00 pm. Food and water were available ad libitum. The 
present study was approved by the Ethics Committee for 
Animal Research of Universidade Federal de São Paulo 
(protocol No. 0252/11) and was performed in compliance 
with the recommendations of the Brazilian Society of Neu-
roscience and Behavior (SBNec), which are based on the 
US National Institutes of Health Guide for Care and Use 
of Laboratory Animals.
Plant material
LA was cultivated in the Medicinal Plant Garden and 
an exsiccate deposited in the Prisco Bezerra Herbarium 
of Universidade Federal do Ceará under No. 24.149. EO 
samples from the leaves of chemotype II were prepared by 
the Laboratory of Natural Products of the University. 
Essential oil
Leaves (1 kg) from chemotype II were collected on 
the same day and at the same time from flowering plants. 
Samples were steam distilled for 1 h. The EO was analyzed 
by GC:MS using a Hewlett-Packard 5971 instrument under 
the following conditions: column, dimethylpolysiloxane 
DB-1 fused-silica capillary column (30 m_0.25 mm); carrier 
gas, helium (1 mL:min); injector temperature, 35-180°C 
at 4°C:min, then 180-250°C at 10°C:min; mass spectrum 
electron impact, 70 eV. Individual components were identi-
fied by spectrometric analysis using two computer library 
MS searches, and Kovats indices as a preselection aid. 
Visual mass spectrum comparison data from the literature 
were used for confirmation.
Compound preparations
EO from chemotype II, (R)-(-)-carvone (Sigma, USA) and 
DZP (Sigma) were suspended in saline with 2% Tween 80. 
Control animals were injected with a vehicle solution (saline 
containing 2% Tween 80). All compounds were prepared 
on the same day of the experiments and administered in-
traperitoneally (ip) in a volume of 1 mL/kg body weight. The 
doses administered in experiments 1 and 2 were chosen on 
the basis of pilot studies conducted in our laboratory, taking 
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into account previously published data (5,16). 
Apparatus
Elevated T-maze. The ETM was made of wood and had 
3 arms of equal dimensions (50 x 12 cm). One arm was 
enclosed by 40-cm high walls and was arranged perpen-
dicularly to two opposed open arms. The entire apparatus 
was elevated 50 cm above the floor. To avoid falls, the open 
arms were surrounded by a Plexiglas rim 1 cm high. 
Open field. For experiment 1, the apparatus used to 
measure locomotion was a square wooden box (60 x 60 
cm), with the floor divided into 9 equal parts, and walls 30 
cm high. 
For experiment 2, the apparatus used was a round 
arena (60 x 60 cm), with the floor divided into 16 parts, 
and walls 50 cm high.
Luminosity at the level of the maze arms or the open 
field center was 60 lux. After each experimental session, 
the models were cleaned with a 10% ethanol solution.
Procedure
Animals were injected ip with the EO from chemotype 
II (12.5 and 25 mg/kg), (R)-(-)-carvone (25 mg/kg), DZP (2 
mg/kg), or vehicle daily for 14 consecutive days. On the 
13th day, each animal was pre-exposed to one of the open 
arms of the ETM for 30 min immediately before treatment. 
It has been shown that pre-exposure shortens escape 
latencies on the test day, rendering the escape test more 
sensitive to the effects of treatment (17). On the follow-
ing day, 30 min after treatment, each animal was placed 
at the distal end of the enclosed arm of the ETM facing 
the intersection of the arms. The time taken by the rat to 
leave this arm, with all four paws, was recorded (baseline 
latency). Avoidance 1 and 2 were measured in the same 
way as baseline latency at 30-s intervals, during which 
animals were placed in a Plexiglas cage to which they had 
been previously habituated. Following avoidance training 
(30 s), rats were placed at the end of one of the open arms 
of the ETM and the time taken to leave this arm with all 
paws was recorded for three consecutive times with 30-s 
intertrial intervals (escape 1, 2, and 3). Immediately after 
being tested in the ETM, each animal was placed for 5 min 
in the open field for further evaluation of locomotor activity. 
During this time, the total number of lines crossed and the 
frequency of rearings were measured. 
Statistical analysis
Repeated measures analysis of variance (ANOVA) was 
used to analyze avoidance and escape measurements, 
with treatment as the independent factor and trials as 
the dependent factor. In the case of significant effects of 
treatment or of the treatment versus trial interaction, data 
were analyzed by the Duncan post hoc test. The open field 
results were submitted to one-way ANOVA followed by the 
Duncan post hoc test. In all cases, a value of P ≤ 0.05 was 
considered to be significant.
Results
Table 1 shows the main components of chemotype II. 
It can be seen through CG:MS analysis that carvone ac-
counts for approximately 55% and limonene for 23% of the 
composition of this chemotype.
Experiment 1 - Effects of chemotype II
The upper panel in Figure 1 shows the anxiolytic ef-
fects of treatment with chemotype II from LA and with DZP 
on ETM avoidance measurements. Repeated measures 
ANOVA showed a significant effect of treatment (F(3,25) 
= 3.81; P = 0.022) and treatment versus trial interaction 
(F(6,50) = 3.54; P = 0.005), but no effect of trials (F(2,50) 
= 2.39; P = 0.102). The Duncan post hoc test showed that 
all treatment groups were significantly different from the 
control group in avoidance 2 (P < 0.05). 
The lower panel in Figure 1 shows absence of effects 
of the same treatments on one-way escape in the ETM. 
Repeated measures ANOVA showed a significant effect 
of trials (F(2,50) = 9.89; P < 0.001), but no effects of treat-
Table 1. Constituents of chemotype II from Lippia alba (Mill) 
N.E.
 
Substance Retention 
time
Kovats 
index
Relative 
percentage (%)
Alpha-thujene 3.37 924 0.28
Alpha-pinene 3.48 928 0.21
Sabinene 4.29 956 2.98
Myrcene 4.68 970 0.46
Limonene 5.69 1005 23.13
Beta-ocimene (Z) 6.11 1020 0.43
Gamma-terpinene 6.62 1038 0.70
Terpinen-4-ol 9.90 1152 0.22
Carvone 12.53 1244 54.57
Isopiperitenone 15.23 1339 0.97
Beta-bourbonene 16.45 1381 0.73
Beta-cubebene 16.67 1389 0.26
Beta-elemene 16.74 1391 0.28
Caryophyllene (E) 17.52 1419 0.34
Aromadendrene Allo 18.80 1463 0.26
Alpha-muurolene 19.55 1490 4.84
Gamma-cadinene 19.93 1503 0.24
Geracrene A 20.20 1500 0.41
Bulnesol 21.68 1564 2.14
Kovats index is a logarithmic scale on which the adjusted reten-
tion time of a peak is compared with those of unbranched al-
kanes. The relative percentage refers to the area calculated un-
der the peak for that specific compound with respect to the total 
peak area.
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ment (F(3,25) = 0.12; P = 0.948) or treatment versus trial 
interaction (F(6,50) = 0.707; P = 0.645). 
One-way ANOVA showed that locomotor activity was 
not changed by drug administration. Neither the number 
of rearings (F(3,25) = 0.811; P = 0.50) nor the number of 
crossings (F(3,25) = 0.793; P = 0.509) were altered by 
treatment with chemotype II from LA or with DZP (data 
not shown). 
Experiment 2 - Effects of (R)-(-)-carvone 
The upper panel in Figure 2 illustrates the anxiolytic 
effects of treatment with (R)-(-)-carvone and DZP on ETM 
avoidance measurements. Repeated measures ANOVA 
showed a significant effect of trials (F(2,50) = 5.43; P = 
0.007), treatment (F(2,25) = 19.79; P < 0.001) and treat-
ment versus trial interaction (F(4,50) = 6.24; P < 0.001). 
The Duncan post hoc test showed that (R)-(-)-carvone was 
significantly different from the control group in avoidance 
1 and that DZP was significantly different from the control 
group in avoidance 1 and 2 (P < 0.05). 
The lower panel in Figure 2 shows absence of effects 
of the same treatments on one-way escape in the ETM. 
Repeated measures ANOVA showed a significant treatment 
versus trial interaction (F(4,50) = 2.93; P = 0.03), but no ef-
fect of trials (F(2,50) = 0.215; P = 0.81) or treatment (F(2,25) 
= 0.114; P = 0.89). The Duncan post hoc test showed that 
neither (R)-(-)-carvone nor DZP were significantly different 
from the control group in any trial.
Again, one-way ANOVA showed that locomotor activity 
was not changed. Neither the number of rearings (F(2,25) = 
2.49; P = 0.10) nor the number of crossings (F(2,25) = 0.31; 
P = 0.74) were altered by treatment with (R)-(-)-carvone or 
with DZP (data not shown). 
Discussion
The results of the present study showed that repeated 
treatment with chemotype II from LA at the two doses admin-
istered (12.5 and 25 mg/kg, ip) decreased ETM avoidance 
latencies, an anxiolytic effect. This same result was also 
observed with (R)-(-)-carvone and with the reference drug 
DZP. Escape measurements, on the other hand, were not 
modified by any of the treatments administered. Since the 
responses measured in the open field were not altered by 
treatment, it is possible to state that the anxiolytic effects 
observed are independent of locomotor alterations. 
Our results are in agreement with previous reports of 
Figure 1. Effects of repeated daily treatment (14 days) with 
chemotype II from Lippia alba and with 2 mg/kg diazepam 
(DZP) on avoidance (upper panel) and escape measurements 
(lower panel) in the elevated T-maze. EO = essential oil. Control 
(N = 8); 12.5 mg/kg EO (N = 7); 25 mg/kg EO (N = 6); DZP (N = 
8). Data are reported as means ± SEM. *P < 0.05 compared to 
control (ANOVA followed by the Duncan post hoc test).
Figure 2. Effects of repeated daily treatment (14 days) with (R)- 
(-)-carvone and with 2 mg/kg diazepam (DZP) on avoidance (upper 
panel) and escape measurements (lower panel) in the elevated T-
maze. Control (N = 12); 25 mg/kg (R)-(-)-carvone (N = 8); DZP (N 
= 8). Data are reported as means ± SEM. *P < 0.05 compared to 
control (ANOVA followed by the Duncan post hoc test).
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anxiolytic effects after acute treatment with higher doses 
(100 and 200 mg/kg, ip) of chemotype II in another animal 
model of anxiety, the elevated plus-maze (5). As observed 
in the present study, there were no changes in the number 
of crossings in the open field, although the dose of 200 mg/
kg altered the number of rearings, indicating a possible 
neurosedative action in this dose range. 
Differently from the elevated plus-maze, which, as 
mentioned, has been considered to be a mixed animal 
model of anxiety (8,9), the ETM allows the measurement of 
two behavioral defensive responses specifically related to 
anxiety disorders found in clinical settings. In this respect, 
one of the main observations of the present study was that 
chemotype II acted selectively on inhibitory avoidance in 
clinical terms related to GAD (11-14). This selective profile 
of action may also explain the controversial effects observed 
with LA (6,7). For instance, it is possible that the lack of anxi-
olysis of some of the isolated constituents previously tested 
(7) reflects the lack of effect of LA on escape responses 
from the open arms of the plus-maze. Thus, further studies 
performed with different chemotypes of LA and other main 
constituents in more selective animal models of anxiety, 
in particular models that measure GAD-related responses 
(see Ref. 10), are still warranted.
In light of our present results, a role for carvone, the 
major constituent of chemotype II, was also suggested. In 
experiment 2, we tested the effects of repeated treatment 
with (R)-(-)-carvone, which in another study had shown a 
more potent neurosedative activity than the enantiometer 
(S)-(+)-carvone (16). Our results showed that (R)-(-)-
carvone decreased avoidance 1 latencies in the same way 
as DZP, without altering escape performance. The effect 
of (R)-(-)-carvone seems to be weaker than that of DZP, at 
least at the dose administered, since the latter drug also 
altered avoidance 2. It is interesting to point out that an 
anxiolytic effect of carvone had been previously proposed 
by Mora et al. (18). These authors investigated the anxiolytic 
and neurosedative effects in different animal models of a 
hydroalcoholic extract of Aloysia polystachya (Griseb.), a 
plant of the Verbenaceae family that is widely distributed 
in subtropical regions of South America and that contains 
carvone as a major constituent.
In fact, previous studies have shown that carvone, a 
monoterpene ketone of the terpenes and the main ac-
tive ingredient of essential oils used in folk medicine and 
in phytotherapy as sedatives or tranquilizers, acts as a 
potent depressor of the central nervous system (16,19). 
For instance, Buchbauer et al. (19) showed that the inha-
lation of two enantiomers of carvone ((S)-(+)-carvone and 
(R)-(-)-carvone) decreases locomotor activity in mice. A 
more recent study (16) indicated that the ip administration 
of these same enantiomers causes different depressant 
effects in mice, such as decreases in ambulation and in 
the reaction to touch, palpebral ptosis, and increases in 
sedation. Also, both enantiomers significantly potentiated 
pentobarbital sleeping time and increased the latency of 
convulsions induced by pentylenetetrazole and picrotoxin 
in a way similar to the reference drug DZP (16). Taking into 
account the depressant effects of carvone and the proposed 
mechanism of action for other monoterpene compounds 
(20), de Sousa et al. (16) suggested that carvone possibly 
interacts with GABAA receptors in the brain after crossing 
the blood-brain barrier. In the light of our present observa-
tions, this fact makes sense. It is possible that carvone 
inhibits neurons, which modulate behavioral inhibition (i.e., 
avoidance responses) in brain areas such as the amygdala 
and the septo-hippocampal system, structures that are 
activated in approach-avoidance conflict situations (10) 
(such as the one present when the animal is placed in the 
enclosed arm of the ETM).
In conclusion, the present results showed that repeated 
treatment with chemotype II from LA exerts anxiolytic-like 
effects on a specific subtype of defensive behavior that has 
been related to GAD in humans. The same was observed 
with (R)-(-)-carvone. Thus, it is possible that carvone, the main 
constituent of chemotype II, is one of the plant’s constituents 
responsible for its therapeutic actions on anxiety. 
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